首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1623513

败血症诊断市场（按技术、产品、病原体、检测类型和地区划分）2024 年至 2031 年

Sepsis Diagnostics Market By Technology, By Product, By Pathogen, By Testing Type & Region for 2024-2031

出版日期: 2024年06月30日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

败血症诊断市场评估，2024 年至 2031 年

败血症诊断市场预计到 2023 年将成长 6.872 亿美元，到 2031 年将成长 14.043 亿美元，预测期内复合年增长率为 8.3%。全球范围内败血症患者数量的不断增加以及人们对该疾病严重性的认识不断提高，推动了对败血症诊断的需求。分子诊断和生物标记等诊断技术的快速发展有助于早期发现和治疗，改善患者的治疗效果。此外，尤其是已开发国家的政府计划和医疗保健系统资金鼓励使用现代诊断设备。医疗相关性感染的增加增加了对准确、快速败血症诊断的需求。

败血症诊断市场定义/概述

败血症诊断是指用于识别败血症的程序和技术，败血症是一种因身体对感染的过度反应而导致的危及生命的疾病。早期诊断对于提高存活率至关重要。血液检测、分子诊断和生物标记识别都是用于检测体内病原体和发炎反应的诊断技术。这些测试使医疗保健专业人员能够更快地发现败血症，从而可以更快地进行治疗并减少因延迟干预而导致的器官衰竭和死亡等併发症。

这些诊断方法分析生物标记、感染和免疫反应，以确定是否有败血症。快速且准确的诊断可以及时干预，减少器官衰竭的机会并提高患者的存活率。败血症诊断可在医院、实验室和护理点使用，帮助指导临床决策、监测患者状况并优化治疗方法，从而获得更好的医疗保健结果。

败血症诊断的未来在于开发更快、更准确和个人化的诊断工具。人工智慧、机器学习和生物标记研究的进步将使更早发现败血症成为可能并改善患者的治疗效果。由于即时诊断和即时监测系统能够在重症监护环境中提供即时结果，因此有望得到更广泛的应用。

慢性疾病和医院内感染将如何影响败血症诊断市场对先进诊断工具的需求？

慢性疾病和医院内感染将对败血症诊断市场对先进诊断设备的需求产生重大影响。患有糖尿病、癌症和呼吸系统疾病等慢性疾病的患者更容易受到感染，并可能发展为败血症。随着这些慢性疾病在世界范围内的发病率不断增加，医疗保健提供者正在寻求更快、更准确的诊断技术，以便更早发现败血症。对快速诊断的迫切需求正在推动对新技术的投资，以改善病原体的检测和监测。

此外，医院内感染 (HAI) 已成为医疗保健环境中的主要问题，导致住院患者败血症发生率不断增加。医院感染管理的复杂性涉及实施先进的诊断技术，以便快速识别病原体及其抗生素敏感性。随着医疗保健系统努力改善患者治疗效果并降低败血症相关死亡率，对改进诊断解决方案的需求也在不断增长，从而推动了败血症诊断市场对快速干预和有针对性的治疗的需求。受到重视。

先进诊断技术的高成本是否限制了其在败血症诊断市场的采用？

目前诊断技术成本高是败血症诊断产业发展的一大阻碍因素，尤其是在资源匮乏的医疗保健环境中。许多医院和诊所，特别是发展中国家的医院和诊所都面临资金限制，无法获得尖端诊断技术。这些医院通常依靠较旧的方法来识别败血症，但这些方法效率较低且更耗时，可能会影响患者的治疗结果。因此，改进的诊断方法的潜在益处仍未充分利用，导致败血症死亡率增加。

此外，实施和维护这项先进技术相关的成本可能会阻止医疗保健提供者进行大量支出。持续的培训和支援的需求进一步加剧了这些限制，从而增加了整体成本。缺乏对高成本诊断的投资可能导致诊断不足和延迟治疗的循环，从而阻碍败血症诊断行业的发展。

The sepsis diagnostics market size was valued at USD 687.2 Million in 2023 and is projected to grow 1404.3 Million by 2031, exhibiting a CAGR of 8.3% during the forecast period. Rising sepsis cases around the world combined with increased awareness of the condition's severity are driving demand for sepsis diagnostics. Rapid advances in diagnostic technology such as molecular diagnostics and biomarkers are accelerating early identification and treatment, resulting in better patient outcomes. Furthermore, government programs and funding in healthcare systems, particularly in developed countries, promote the use of modern diagnostic equipment. The increasing prevalence of healthcare-associated infections is exacerbating the need for accurate and rapid sepsis diagnosis.

Sepsis Diagnostics Market: Definition/ Overview

Sepsis diagnostics refers to the procedures and technologies used to identify sepsis, which is a life-threatening condition caused by the body's overreaction to infection. Early diagnosis is crucial for increasing survival rates. Blood testing, molecular diagnostics, and biomarker identification are all diagnostic techniques used to detect pathogens and inflammatory responses in the body. These tests enable healthcare practitioners to detect sepsis rapidly allowing for immediate treatment and decreasing complications such as organ failure or death caused by delayed intervention.

These diagnostics analyze biomarkers, infections, and immune responses to determine the existence of sepsis. Rapid and precise diagnosis allows for timely intervention which reduces the chance of organ failure and increases patient survival rates. Sepsis diagnostics are utilized in hospitals, laboratories, and point-of-care settings to help guide clinical decisions, monitor patient states, and optimize treatment approaches resulting in better healthcare outcomes.

The future of sepsis diagnostics lies in the development of faster, more accurate, and personalized diagnostic tools. Advancements in artificial intelligence, machine learning, and biomarker research will enable earlier detection of sepsis, improving patient outcomes. Point-of-care testing and real-time monitoring systems are expected to become more widespread offering immediate results in critical care settings.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How do Chronic Diseases and Hospital-Acquired Infections Influence the Demand for Advanced Diagnostic Tools in the Sepsis Diagnostics Market?

Chronic diseases and hospital-acquired infections have a substantial impact on the demand for enhanced diagnostic instruments in the sepsis diagnostics market. Patients with chronic disorders such as diabetes, cancer, and respiratory problems are more vulnerable to infections which can progress to sepsis. As the global frequency of these chronic diseases rises, healthcare providers are looking for faster and more accurate diagnostic techniques to detect sepsis in its early stages. This important need for fast diagnosis drives investments in new technologies that improve pathogen detection and monitoring.

Furthermore, hospital-acquired infections (HAIs) are becoming a major concern in healthcare settings, resulting in the increasing incidence of sepsis among hospitalized patients. The complexity of HAI management involves the deployment of sophisticated diagnostic technologies capable of swiftly identifying the causative agents and their antibiotic susceptibility. As healthcare systems work to improve patient outcomes and reduce sepsis-related mortality, the demand for improved diagnostic solutions will increase, emphasizing the necessity of prompt intervention and focused therapeutics in the sepsis diagnostics market.

How Does the High Cost of Advanced Diagnostic Technologies Serve as a Restraint to Widespread Adoption in the Sepsis Diagnostics Market?

The high cost of modern diagnostic technologies severely limits widespread use in the sepsis diagnostics industry, especially in resource-constrained healthcare settings. Many hospitals and clinics, particularly in developing countries, confront financial constraints that restrict them from adopting cutting-edge diagnostic technologies. These hospitals frequently rely on older methods for identifying sepsis which can be less effective and slower, affecting patient outcomes. As a result, the potential benefits of improved diagnostics remain underutilized contributing to greater sepsis death rates.

Furthermore, the cost burden associated with deploying and maintaining this advanced technology may discourage healthcare providers from making critical expenditures. This constraint is exacerbated by the requirement for continual training and assistance which increases the overall cost. Reluctance to invest in high-cost diagnostics might lead to a loop of underdiagnosis and delayed treatment impeding growth in the sepsis diagnostics sector.

Category-Wise Acumens

How do Advancements in Blood Culture Technology Improve the Detection of Pathogens in Sepsis Cases?

Blood culture media are dominant in the sepsis diagnostics market primarily due to their crucial role in identifying the pathogens responsible for sepsis. These media facilitate the growth of bacteria and fungi from blood samples enabling accurate and timely diagnosis. The ability to detect a wide range of microorganisms including those that are fastidious or present in low concentrations, makes blood culture a gold standard in sepsis diagnostics. As early detection is vital for effective treatment, the reliability and sensitivity of blood culture media significantly contribute to their prevalence in clinical settings.

Furthermore, advancements in blood culture technology such as automated systems that monitor growth and provide rapid results enhance their effectiveness. Innovations like continuous monitoring and improved sensitivity have expanded their utility in diagnosing sepsis even in challenging cases. As healthcare systems increasingly prioritize early intervention and precise diagnostics to improve patient outcomes, the demand for blood culture media continues to grow solidifying their dominant position in the market.

How Does the Diversity and Evolution of Sepsis-Causing Pathogens Challenge Traditional Diagnostic Methods?

Molecular diagnostics is more dominant in the sepsis diagnostics market due to its ability to provide rapid and accurate identification of pathogens causing sepsis. Unlike traditional culture methods which can take days to yield results, molecular techniques such as polymerase chain reaction (PCR) and next-generation sequencing deliver results in a matter of hours. This speed is crucial for timely treatment decisions, significantly improving patient outcomes and reducing mortality rates associated with sepsis.

Furthermore, molecular diagnostics can detect a wide variety of pathogens including bacteria, viruses, and fungi, in a single test. This extensive detection capability is critical given the diversity and evolution of sepsis-causing pathogens. As healthcare practitioners recognize the value of early intervention, the demand for better diagnostic technologies grows. The growing use of point-of-care testing increases the accessibility and utility of molecular diagnostics in critical care settings cementing its dominance in the sepsis diagnostics market.

Sepsis Diagnostics Market

Report Methodology

Country/Region-wise Acumens

How do Increased Awareness and Education among Healthcare Professionals and Patients Affect the Sepsis Diagnostics Market in the North American Region?

North America dominates the sepsis diagnostics market because of its advanced healthcare infrastructure and large spending on medical research & development. The region is home to many top diagnostic firms and research organizations that promote innovation in sepsis detection methods. This has resulted in the development of cutting-edge treatments like molecular diagnostics and quick testing systems which allow healthcare providers to identify sepsis more effectively and efficiently.

Furthermore, the rising occurrence of sepsis, together with increased awareness among healthcare professionals and patients drives market expansion. The presence of well-established healthcare systems promotes the use of advanced diagnostic technologies which improves patient outcomes. Furthermore, legislative and financing initiatives in North America promote the development and commercialization of novel diagnostic technology. As a result, North America continues to dominate the sepsis diagnostics industry using its strengths in technology, research, and healthcare delivery.

How Does the Developing Healthcare Infrastructure Influence the Adoption of Modern Diagnostic Tools for Sepsis in the Asia-Pacific Region?

Asia Pacific is the fastest-growing area in the sepsis diagnostics market owing to a rapidly growing patient population fuelled by rising infection rates, chronic diseases, and an aging demographic. The region's developing healthcare infrastructure combined with significant government investment in healthcare innovations encourages the use of modern diagnostic tools. As knowledge of sepsis and its serious effects develops, healthcare providers are focussing more on strengthening diagnostic capabilities to ensure timely and successful treatment.

Furthermore, the growth of biotechnology and pharmaceutical companies in countries such as China and India creates a competitive climate for producing sophisticated diagnostics. The increasing demand for point-of-care testing and molecular diagnostics is also propelling expansion in this sector. Furthermore, the rising prevalence of hospital-acquired infections and the necessity for rapid diagnostic solutions in healthcare facilities highlight the importance of effective sepsis diagnostics. These factors combine to position Asia Pacific as a major participant in the global sepsis diagnostics market.

Competitive Landscape

The Sepsis Diagnostics Market is a dynamic and competitive space characterized by diverse players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations focus on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the sepsis diagnostics market include:

Abbott Laboratories, Becton Dickinson and Company, BioMerieux, Luminex, Danaher, T2 Biosystems, Thermo Fisher Scientific, Roche Diagnostics, Bruker, Immunexpress.

Latest Developments

In April 2024, The US Food and Drug Administration (FDA) approved Prenosis' AI tool Sepsis ImmunoScore to diagnose sepsis. This authorization, obtained through the De Novo procedure, is the first FDA approval of an AI/machine learning (ML) software as a medical device (SaMD) for sepsis detection and prediction.

In May 2024, Cytovale, a medical diagnostics company, announced the publication of data demonstrating that its sepsis diagnosis tool IntelliSep has a negative predictive value of 97.5 percent. The FDA-approved IntelliSep technology allows for the rapid detection of sepsis in adults who exhibit signs and symptoms of infection by squeezing white blood cells to characterize their reactions to infection.

1 INTRODUCTION OF GLOBAL SEPSIS DIAGNOSTICS MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL SEPSIS DIAGNOSTICS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY

5.1 Overview
5.2 Microbiology
5.3 Molecular Diagnostics
5.4 Immunoassays

6 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY PRODUCT

6.1 Overview
6.2 Assay and reagents
6.3 Blood culture media
6.4 Instruments

7 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN

7.1 Overview
7.2 Fungal sepsis
7.3 Bacterial sepsis

8 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY TESTING TYPE

8.1 Overview
8.2 Laboratory Tests
8.3 Point-of-care Tests

9 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East & Africa

10 GLOBAL SEPSIS DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Abbott Laboratories
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Becton, Dickinson and Company
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 BioMerieux
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Luminex
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Danaher
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 T2 Biosystems
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Thermo Fisher Scientific
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Roche Diagnostics
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Bruker
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Immunexpress
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments